Low frequency of drug-resistant variants selected by long-acting rilpivirine in macaques infected with simian immunodeficiency virus containing HIV-1 reverse transcriptase

Kevin Melody, Sarah McBeth, Christopher Kline, Angela D.M. Kashuba, John W. Mellors, Zandrea Ambrose

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Preexposure prophylaxis (PrEP) using antiretroviral drugs is effective in reducing the risk of human immunodeficiency virus type 1 (HIV-1) infection, but adherence to the PrEP regimen is needed. To improve adherence, a long-acting injectable formulation of the nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV LA) has been developed. However, there are concerns that PrEP may select for drug-resistant mutations during preexisting or breakthrough infections, which could promote the spread of drug resistance and limit options for antiretroviral therapy. To address this concern, we administered RPV LA to macaques infected with simian immunodeficiency virus containing HIV-1 RT (RT-SHIV). Peak plasma RPV levels were equivalent to those reported in human trials and waned over time after dosing. RPV LA resulted in a 2-log decrease in plasma viremia, and the therapeutic effect was maintained for 15 weeks, until plasma drug concentrations dropped below 25 ng/ml. RT mutations E138G and E138Q were detected in single clones from plasma virus in separate animals only at one time point, and no resistance mutations were detected in viral RNA isolated from tissues. Wild-type and E138Q RT-SHIV displayed similar RPV susceptibilities in vitro, whereas E138G conferred 2-fold resistance to RPV. Overall, selection of RPV-resistant variants was rare in an RTSHIV macaque model despite prolonged exposure to slowly decreasing RPV concentrations following injection of RPV LA.

Original languageEnglish (US)
Pages (from-to)7762-7770
Number of pages9
JournalAntimicrobial Agents and Chemotherapy
Volume59
Issue number12
DOIs
StatePublished - Dec 1 2015
Externally publishedYes

Fingerprint

Rilpivirine
Simian Immunodeficiency Virus
Macaca
HIV-1
RNA-Directed DNA Polymerase
Pharmaceutical Preparations
Mutation
Injections
Reverse Transcriptase Inhibitors
Viremia
Viral RNA
Therapeutic Uses
Virus Diseases
Drug Resistance
Clone Cells
Viruses
Human immunodeficiency virus 1 reverse transcriptase
Infection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Low frequency of drug-resistant variants selected by long-acting rilpivirine in macaques infected with simian immunodeficiency virus containing HIV-1 reverse transcriptase. / Melody, Kevin; McBeth, Sarah; Kline, Christopher; Kashuba, Angela D.M.; Mellors, John W.; Ambrose, Zandrea.

In: Antimicrobial Agents and Chemotherapy, Vol. 59, No. 12, 01.12.2015, p. 7762-7770.

Research output: Contribution to journalArticle

Melody, Kevin ; McBeth, Sarah ; Kline, Christopher ; Kashuba, Angela D.M. ; Mellors, John W. ; Ambrose, Zandrea. / Low frequency of drug-resistant variants selected by long-acting rilpivirine in macaques infected with simian immunodeficiency virus containing HIV-1 reverse transcriptase. In: Antimicrobial Agents and Chemotherapy. 2015 ; Vol. 59, No. 12. pp. 7762-7770.
@article{24be2b2196f84dc1a18b70bd8d0ef7e0,
title = "Low frequency of drug-resistant variants selected by long-acting rilpivirine in macaques infected with simian immunodeficiency virus containing HIV-1 reverse transcriptase",
abstract = "Preexposure prophylaxis (PrEP) using antiretroviral drugs is effective in reducing the risk of human immunodeficiency virus type 1 (HIV-1) infection, but adherence to the PrEP regimen is needed. To improve adherence, a long-acting injectable formulation of the nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV LA) has been developed. However, there are concerns that PrEP may select for drug-resistant mutations during preexisting or breakthrough infections, which could promote the spread of drug resistance and limit options for antiretroviral therapy. To address this concern, we administered RPV LA to macaques infected with simian immunodeficiency virus containing HIV-1 RT (RT-SHIV). Peak plasma RPV levels were equivalent to those reported in human trials and waned over time after dosing. RPV LA resulted in a 2-log decrease in plasma viremia, and the therapeutic effect was maintained for 15 weeks, until plasma drug concentrations dropped below 25 ng/ml. RT mutations E138G and E138Q were detected in single clones from plasma virus in separate animals only at one time point, and no resistance mutations were detected in viral RNA isolated from tissues. Wild-type and E138Q RT-SHIV displayed similar RPV susceptibilities in vitro, whereas E138G conferred 2-fold resistance to RPV. Overall, selection of RPV-resistant variants was rare in an RTSHIV macaque model despite prolonged exposure to slowly decreasing RPV concentrations following injection of RPV LA.",
author = "Kevin Melody and Sarah McBeth and Christopher Kline and Kashuba, {Angela D.M.} and Mellors, {John W.} and Zandrea Ambrose",
year = "2015",
month = "12",
day = "1",
doi = "10.1128/AAC.01937-15",
language = "English (US)",
volume = "59",
pages = "7762--7770",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Low frequency of drug-resistant variants selected by long-acting rilpivirine in macaques infected with simian immunodeficiency virus containing HIV-1 reverse transcriptase

AU - Melody, Kevin

AU - McBeth, Sarah

AU - Kline, Christopher

AU - Kashuba, Angela D.M.

AU - Mellors, John W.

AU - Ambrose, Zandrea

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Preexposure prophylaxis (PrEP) using antiretroviral drugs is effective in reducing the risk of human immunodeficiency virus type 1 (HIV-1) infection, but adherence to the PrEP regimen is needed. To improve adherence, a long-acting injectable formulation of the nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV LA) has been developed. However, there are concerns that PrEP may select for drug-resistant mutations during preexisting or breakthrough infections, which could promote the spread of drug resistance and limit options for antiretroviral therapy. To address this concern, we administered RPV LA to macaques infected with simian immunodeficiency virus containing HIV-1 RT (RT-SHIV). Peak plasma RPV levels were equivalent to those reported in human trials and waned over time after dosing. RPV LA resulted in a 2-log decrease in plasma viremia, and the therapeutic effect was maintained for 15 weeks, until plasma drug concentrations dropped below 25 ng/ml. RT mutations E138G and E138Q were detected in single clones from plasma virus in separate animals only at one time point, and no resistance mutations were detected in viral RNA isolated from tissues. Wild-type and E138Q RT-SHIV displayed similar RPV susceptibilities in vitro, whereas E138G conferred 2-fold resistance to RPV. Overall, selection of RPV-resistant variants was rare in an RTSHIV macaque model despite prolonged exposure to slowly decreasing RPV concentrations following injection of RPV LA.

AB - Preexposure prophylaxis (PrEP) using antiretroviral drugs is effective in reducing the risk of human immunodeficiency virus type 1 (HIV-1) infection, but adherence to the PrEP regimen is needed. To improve adherence, a long-acting injectable formulation of the nonnucleoside reverse transcriptase (RT) inhibitor rilpivirine (RPV LA) has been developed. However, there are concerns that PrEP may select for drug-resistant mutations during preexisting or breakthrough infections, which could promote the spread of drug resistance and limit options for antiretroviral therapy. To address this concern, we administered RPV LA to macaques infected with simian immunodeficiency virus containing HIV-1 RT (RT-SHIV). Peak plasma RPV levels were equivalent to those reported in human trials and waned over time after dosing. RPV LA resulted in a 2-log decrease in plasma viremia, and the therapeutic effect was maintained for 15 weeks, until plasma drug concentrations dropped below 25 ng/ml. RT mutations E138G and E138Q were detected in single clones from plasma virus in separate animals only at one time point, and no resistance mutations were detected in viral RNA isolated from tissues. Wild-type and E138Q RT-SHIV displayed similar RPV susceptibilities in vitro, whereas E138G conferred 2-fold resistance to RPV. Overall, selection of RPV-resistant variants was rare in an RTSHIV macaque model despite prolonged exposure to slowly decreasing RPV concentrations following injection of RPV LA.

UR - http://www.scopus.com/inward/record.url?scp=84954495868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954495868&partnerID=8YFLogxK

U2 - 10.1128/AAC.01937-15

DO - 10.1128/AAC.01937-15

M3 - Article

VL - 59

SP - 7762

EP - 7770

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 12

ER -